Pyrimethamine

Generic Name
Pyrimethamine
Brand Names
Daraprim
Drug Type
Small Molecule
Chemical Formula
C12H13ClN4
CAS Number
58-14-0
Unique Ingredient Identifier
Z3614QOX8W
Background

One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

Indication

For the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine

Associated Conditions
Toxoplasmosis
Associated Therapies
-
Clinical Trials
Related News

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

Early Phase 1
Recruiting
Conditions
Head and Neck Cancer
Cancer of the Head and Neck
Interventions
Drug: Pyrimethamine
First Posted Date
2023-01-10
Last Posted Date
2024-04-22
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
20
Registration Number
NCT05678348
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Phase 1
Completed
Conditions
Healthy Male Volunteers
Interventions
Drug: BMS-986165
Drug: Pyrimethamine
First Posted Date
2019-09-12
Last Posted Date
2020-08-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT04086719
Locations
🇺🇸

PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...

First Posted Date
2019-05-16
Last Posted Date
2022-07-12
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
252
Registration Number
NCT03952650
Locations
🇲🇱

Malaria Vaccine Center STTB/MRTC, Bamako, Mali

LRAs United as a Novel Anti-HIV Strategy.

Phase 1
Completed
Conditions
HIV-1-infection
Interventions
Drug: Valproic Acid
Drug: Pyrimethamine
First Posted Date
2018-05-16
Last Posted Date
2021-04-29
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
28
Registration Number
NCT03525730
Locations
🇳🇱

Erasmus MC, Rotterdam, Netherlands

Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects

Phase 1
Completed
Conditions
Toxoplasmosis
Interventions
Drug: Pyrimethamine
Drug: Calcium folinate
First Posted Date
2017-08-23
Last Posted Date
2020-03-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
14
Registration Number
NCT03258762
Locations
🇦🇺

GSK Investigational Site, Melbourne, Victoria, Australia

Dose Escalation PfSPZ-CVac

First Posted Date
2017-03-20
Last Posted Date
2021-06-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
55
Registration Number
NCT03083847
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Phase 1
Withdrawn
Conditions
Myelodysplastic Syndromes
Interventions
Drug: Pyrimethamine
First Posted Date
2017-02-20
Last Posted Date
2021-09-22
Lead Sponsor
Montefiore Medical Center
Registration Number
NCT03057990
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)

First Posted Date
2010-04-13
Last Posted Date
2012-02-23
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
20
Registration Number
NCT01102686
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Phase 1
Completed
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Drug: Pyrimethamine
First Posted Date
2010-03-10
Last Posted Date
2017-06-19
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
32
Registration Number
NCT01083667
Locations
🇩🇪

Universitäts- und Rehabilitationskliniken Ulm, Ulm, Germany

🇺🇸

Methodist Neurological Institute, Houston, Texas, United States

🇺🇸

Weill Cornell Medical Center/New York Presbyterian Hospital, New York, New York, United States

and more 2 locations

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

First Posted Date
2010-02-10
Last Posted Date
2023-02-22
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
20
Registration Number
NCT01066663
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy